Login to Your Account



Ignoring Shareholders Puts Industry Investment at Risk

By Jennifer Boggs


Monday, December 22, 2008
Back in early October, the future was looking pretty good for Avigen Inc. Its stock was trading above $3 and it was awaiting data on lead program AV562, with plans for additional pipeline programs down the road.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription